Thomas, GR; DiFabio, JM; Gori, T et al.
Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism.J Am Coll Cardiol. Bd. 49. H. 12. 2007 S. 1289-95
Hink, U; Daiber, A; Kayhan, N et al.
Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels.J Am Coll Cardiol. Bd. 50. H. 23. 2007 S. 2226-32
Schnabel, R; Blankenberg, S
Oxidative stress in cardiovascular disease: successful translation from bench to bedside?Circulation. Bd. 116. H. 12. 2007 S. 1338-40
Schlitt, A; Heine, GH; Jiang, XC et al.
Phospholipid Transfer Protein in Hemodialysis Patients.Am J Nephrol. Bd. 27. 2007 S. 138-143
Koenig, A; Lange, K; Konter, J et al.
Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.J Cardiovasc Pharmacol. Bd. 50. H. 1. 2007 S. 68-74
Sinning, JM; Bickel, C; Sinning, C et al.
Procalcitonin for risk stratification in stable coronary artery disease: Results from the atherogene studyCirculation. Bd. 116. H. 16. 2007 S. 851
Morange, PE; Blankenberg, S; Alessi, MC et al.
Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study.J Thromb Haemost. Bd. 5. 2007 S. 475-482
Fajadet, J; Wijns, W; Laarman, GJ et al.
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.Minerva Cardioangiol. Bd. 55. H. 1. 2007 S. 1-18
Gori, T; Fineschi, M
Recurrent angina and the problem of inadequate/inappropriate revascularizationEur Heart J. Bd. 28. H. 23. 2007 S. 2951; author reply 2951-2
Gradaus, R; Seidl, K; Korte, T et al.
Reduction of ventricular tachyarrhythmia by treatment of atrial fibrillation in ICD patients with dual-chamber implantable cardioverter/defibrillators capable of atrial therapy delivery: the REVERT-AF Study.Europace. Bd. 9. H. 7. 2007 S. 534-9